Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Vaccine

Volumn 34, Issue 49, 2016, Pages 6093-6101

  Harrison, Margo S ^a   Eckert, Linda O ^b   Cutland, Clare ^c   Gravett, Michael ^d   Harper, Diane M ^e   McClure, Elizabeth M ^f   Nunes, Anthony P ^g   Lazo, Suzette ^h   Moore, Tamala Mallett ⁱ   Watson, Wendy ^j   Kochhar, Sonali ^k   Goldenberg, Robert L ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Global Alliance to Prevent Prematurity and Stillbirth   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f RTI INTERNATIONAL   (United States)

^g OPTUM   (United States)

^h Philippine Society of Experimental and Clinical Pharmacology   (Philippines)

ⁱ SANOFI PASTEUR   (France)

^j PFIZER INC   (United States)

^k Global Healthcare Consulting   (India)

more..

Author keywords

Adverse event; Case definition; Guidelines; Immunization; Insufficient cervix; Preterm birth; Preterm labor; Preterm premature rupture of membranes; Provider initiated preterm birth

Indexed keywords

ARTICLE; DISEASE COURSE; DRUG SAFETY; HUMAN; IMMUNIZATION; INFORMATION PROCESSING; PRACTICE GUIDELINE; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX DISEASE; DRUG SURVEILLANCE PROGRAM; FEMALE; NEWBORN; PREGNANCY; PREMATURITY;

VACCINE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNIZATION; INFANT, NEWBORN; PREGNANCY; PREMATURE BIRTH; RISK FACTORS; VACCINES;

EID: 84998887053     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.054     Document Type: Article

References (17)

1. [1] Rubens, C.E., Sadovsky, Y., Muglia, L., Gravett, M.G., Lackritz, E., Gravett, C., Prevention of preterm birth: harnessing science to address the global epidemic. Sci Transl Med 6:262 (2014), 1–12.
2. [2] Kramer, M.S., Papageorghiou, A., Culhane, J., Bhutta, Z., Goldenberg, R.L., Gravett, M., et al. Challenges in defining and classifying the preterm birth syndrome. AJOG, 2012, 108–112.
3. [3] Moro, P.L., Broder, K., Zheteyeva, Y., Revzina, N., Tepper, N., Kissin, D., et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported in the Vaccine Adverse Event Reporting System. AJOG 205:473 (2011), e1–e9.
4. [4] Lannon, S.M.R., Vanderhoeven, J.P., Eschenbach, D.A., Gravett, M.G., Adams Waldorf, K.A., Synergy and interactions among biological pathways leading to preterm premature rupture of membranes. Reprod Sci 21:10 (2014), 1215–1227.
5. [5] Alper, U., Dewan, A.T., Istrail, S., Padbury, J.F., Pathway-based genetic analysis of preterm birth. Genomics 101:3 (2013), 163–170.
6. [6] Romero, R., Dey, S.K., Fisher, S.J., Preterm labor: one syndrome, many causes. Science 345:6198 (2014), 760–765.
7. [7] Rust, O., Odibo, A., Practice Bulletin No. 142. American College of Obstetricians and Gynecologists. Obstet Gynecol 123 (2014), 372–379.
8. [8] Bannerman, C., Fuchs, K.M., Young, O.M., Hoffman, M.K., Nonspontaneous late preterm birth: etiology and outcomes. Am J Obstet Gynecol 205:456 (2011), e1–e6.
9. [9] Cerclage for the management of cervical insufficiency. Practice Bulletin No. 142. American College of Obstetricians and Gynecologists. Obstet Gynecol 123 (2014), 372–379.
10. [10] Wong, A.E., Grobman, W.A., Medically indicated-iatrogenic prematurity. Clin Perinatol 38 (2011), 423–439.
11. [11] Van der Ham, D.P., van Melick, M.J.G.J., Smits, L., Nijhuis, J.G., Weiner, C.P., van Beek, J.H.J., et al. Methods for the diagnosis of rupture of fetal membranes in equivocal cases: a systematic review. Eur J Obstet Gynecol Reprod Biol 157 (2011), 123–127.
12. [12] Blencowe, H., Cousens, S., Oestergaard, M., Chou, D., Moller, A.B., Narwal, R., et al. National, regional and worldwide estimates of preterm birth rates in the year 2010 with time trends for selected countries since 1990: a systematic analysis and implications. Lancet 379 (2012), 2162–2172.
13. [13] International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/products/guidelines.html [accessed 09.07.15].
14. [14] Council for International Organizations of Medical Sciences. http://www.cioms.ch/index.php/cioms-form-i [accessed 09.07.15].
15. [15] Moher, D., Schulz, K.F., Altman, D., Group, C., The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:15 (2001), 1987–1991.
16. [16] Moher, D., Cook, D.J., Eastwood, S., Olkin, I., Rennie, D., Stroup, D.F., Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:9193 (1999), 1896–1900.
17. [17] Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis OF Observational Studies in Epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.